BridgeBio (BBIO) Pharma published an analysis of genetic and health data from more than 700,000 individuals in the American Journal of Human Genetics, confirming prior estimates of the genetic prevalence of autosomal dominant hypocalcemia type 1 and underscoring opportunities to elevate diagnostic suspicion. CALIBRATE, BridgeBio’s Phase 3 clinical trial of encaleret for ADH1, a condition caused by activating variants of the CASR, is fully enrolled with 71 participants. The registrational study is the largest prospective interventional study ever to be conducted in ADH1. The Company expects to report topline results in the second half of 2025. If successful, encaleret would be the first approved therapy for individuals living with ADH1. The Company also intends to initiate a registrational study of encaleret in chronic hypoparathyroidism, another condition linked with the newly found CASR allelic series, in 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio initiated with a Buy at Truist
- These 2 Momentum Stocks Got a Bullish Nod — Here’s Why They Could Reach New Highs
- BridgeBio Pharma’s Promising Diversification and High-Margin Opportunities Drive Buy Rating
- Rivian downgraded, PayPal upgraded: Wall Street’s top analyst calls
- BridgeBio price target raised to $56 from $53 at Leerink